Impact of plasma Epstein–Barr virus DNA in posttreatment nasopharyngeal carcinoma patients after SARS-CoV-2 infection

Cheng Lin,Meifang Li,Yingying Lin,Yu Zhang,Hanchuan Xu,Bijuan Chen,Xia Yan,Yun Xu

DOI: https://doi.org/10.1186/s13027-024-00570-x

2024-03-16

Infectious Agents and Cancer

Abstract:Nasopharyngeal carcinoma (NPC) is prevalent in southern China. EBV DNA is the most useful biomarker in NPC. However, the value of EBV DNA in posttreatment NPC patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unclear.

oncology,immunology

What problem does this paper attempt to address?

The paper primarily explores the effectiveness of Epstein–Barr virus (EBV) DNA in the plasma of nasopharyngeal carcinoma (NPC) patients as a recurrence monitoring indicator after infection with the novel coronavirus (SARS-CoV-2). Specifically, the study aims to address the following issues:

1. **Reliability of EBV DNA in NPC patients after COVID-19 infection**: The study investigates whether the detection of EBV DNA in some NPC patients, which changes from undetectable to detectable after COVID-19 infection, indicates tumor progression or recurrence.
2. **Relationship between changes in EBV DNA and recurrence**: By comparing the EBV DNA levels of recurrent and non-recurrent patients, the study evaluates the effectiveness of EBV DNA in predicting NPC recurrence.
3. **Optimal monitoring scheme**: The study aims to determine how to reasonably arrange the frequency and timing of EBV DNA monitoring during the COVID-19 pandemic.

In summary, the main purpose of the paper is to assess whether EBV DNA can be used alone to monitor the recurrence of NPC patients during the COVID-19 pandemic and to propose reasonable monitoring recommendations.